Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Regen BioPharma (RGBPP) over the last 10 years, with Q4 2025 value amounting to $2.5 million.

  • Regen BioPharma's Other Non-Current Liabilities rose 3518.13% to $2.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 million, marking a year-over-year increase of 3518.13%. This contributed to the annual value of $2.1 million for FY2025, which is 4811.14% up from last year.
  • As of Q4 2025, Regen BioPharma's Other Non-Current Liabilities stood at $2.5 million, which was up 3518.13% from $2.1 million recorded in Q3 2025.
  • Regen BioPharma's Other Non-Current Liabilities' 5-year high stood at $70.6 million during Q1 2022, with a 5-year trough of $302391.0 in Q1 2021.
  • Its 5-year average for Other Non-Current Liabilities is $5.9 million, with a median of $1.7 million in 2025.
  • As far as peak fluctuations go, Regen BioPharma's Other Non-Current Liabilities surged by 2323462.97% in 2022, and later tumbled by 9801.59% in 2023.
  • Over the past 5 years, Regen BioPharma's Other Non-Current Liabilities (Quarter) stood at $3.9 million in 2021, then crashed by 63.44% to $1.4 million in 2022, then fell by 2.5% to $1.4 million in 2023, then soared by 30.01% to $1.8 million in 2024, then surged by 35.18% to $2.5 million in 2025.
  • Its Other Non-Current Liabilities was $2.5 million in Q4 2025, compared to $2.1 million in Q3 2025 and $1.8 million in Q2 2025.